Ongoing advances in the diagnosis and treatment of breast cancer have prompted a sharp decline in breast cancer mortality rates. Indeed, in October 2017, the American Cancer Society reported a 39% drop in these rates between 1989 and 2015 for women over 50. That’s 322,600 lives saved in 26 years.1

Today, women have multiple treatment choices for breast cancer—from traditional surgery, chemotherapy and radiation therapy, to newer options in immunotherapy and targeted therapy. Yet, even conventional therapies are undergoing changes as researchers and clinicians investigate emerging technologies such as stereotactic body radiation therapy (SBRT).

One of the largest SBRT practices in the United States is at NYU Winthrop Hospital in Mineola, New York, under the direction of Jonathan A. Haas, MD, chairman, Department of Radiation Oncology. In 2011, Dr. Haas launched a study, which obtained internal review board (IRB) approval, to evaluate the treatment of early stage breast cancer with SBRT. He collaborated with Sandra S. Vermeulen, MD, executive director of the Swedish Radiosurgery Center at Swedish Medical Center, Seattle, Washington, and together they treated 65 breast cancer patients with the CyberKnife (Accuray, Sunnyvale, California) (Figure 1).

Dr. Haas presented their data at ASTRO 2017 in San Diego, and reported a 98% control rate at the 5-year follow-up. “That’s better than any other adjuvant treatment for breast cancer that’s out there,” he says, acknowledging that although one patient relapsed, it was in a different quadrant of her breast and possibly a different cancer.

His treatment protocol in the study is based on accelerated partial breast irradiation (APBI) guidelines by the Radiation Therapy Oncology Group (RTOG). Patient eligibility and selection is a critical component, consisting of women with a tumor < 3 cm, margins negative by > 2 mm, a surgical cavity distance of 5 to 7 cm from the skin line, no positive lymph nodes, and exclusion of patients with invasive lobular carcinoma.

“Compared to other accelerated partial breast treatments, the major advantage of SBRT is not inserting a catheter into the breast for treatment,” Dr. Haas says. “As long as there is proper patient selection, I don’t think there are any disadvantages for patients. It is less invasive, more comfortable and more convenient. Compared to 4 to 6 weeks of daily treatment for whole-breast radiation therapy, this is only 5 treatment days, which is a huge benefit for our patients.”

In general, SBRT also is a more precise way to deliver radiation therapy, says Steven Feigenberg, MD, professor and vice chair of clinical research, and chief of thoracic radiation oncology at the Hospital of the University of Pennsylvania, Perelman Center for Advanced Medicine. In conventional radiation therapy planning, a margin of 5 to 10 mm is added to the target to account for intrafractional and interfractional setup uncertainties; however, SBRT typically can reduce those margins to 1 to 2 mm.

Dr. Feigenberg explains that SBRT in the United States typically involves 1 to 5 treatments, depending on tumor size and proximity to surrounding normal tissues. While most breast SBRT is performed following surgery, a group at Duke University School of Medicine led by Janet K. Horton, MD, has

**Ms. Massat is a freelance healthcare writer based in Crystal Lake, IL.**
examined preoperative single-fraction APBI in a phase 1 study. The authors reported that the therapy was well tolerated and should continue clinical trial testing as it may also enable identification of radiation response biomarkers. Currently, they are accruing patients in a phase II study.

“A very interesting aspect of preoperative radiation therapy is the potential for improvement in cosmesis as compared to conventional 3-dimensional (3D) APBI,” Dr. Feigenberg says. “The key to the benefits of preoperative therapy is the substantial reduction in normal breast being radiated, which theoretically improves cosmesis; makes more people eligible for 3D APBI; and decreases dose to all surrounding normal structures, reducing the morbidity of therapy.”

SBRT is also a treatment that patients want, says Elizabeth Nichols, MD, assistant professor of radiation oncology, and clinical director of the Department of Radiation Oncology, University of Maryland School of Medicine (UMSOM). In addition to decreased toxicity to surrounding tissue and enhanced patient convenience with fewer treatments, SBRT may be more cost-effective for a health system.

“For every day that we deliver radiation therapy, there is a cost associated with that,” Dr. Nichols explains. “Therapies with a longer course of treatment will cost more. However, we also believe there is the potential for decreased side effects with SBRT compared to whole-breast irradiation, so downstream there are potentially fewer costs.”

Current Challenges

A significant hurdle to providing SBRT for breast cancer is lack of reimbursement—a key reason Dr. Haas opened his study. As the data matures and SBRT is viewed as safe and effective for early stage breast cancer—as well as more convenient and potentially more cost-effective—he is hopeful insurors will initiate coverage.

Dr. Nichols also notes that Medicare does not cover breast SBRT, due in part to a mismatch between what clinicians and insurers label as SBRT. “SBRT is a high dose per fraction, in just a few fractions, using image guidance with a very sharp dose gradient outside the tumor and in the surrounding tissue,” she explains. Since breast SBRT is new and evolving, insurers may not be aware of the treatment efficacy and patient outcomes from recent and ongoing clinical studies.

It would also be helpful for any type of SBRT procedure to have a real-time tumor tracking system, says Dr. Feigenberg. “A system that could do the tracking with a marker inside the tumor in real-time during treatment is the holy grail,” he says. While several techniques use surrogate markers and rely on surface imaging to monitor tumor movement, they are not 100%, he adds.

Plus, placement of surrogate markers for image guidance can be difficult, says Dr. Haas. If these are inserted during a lumpectomy, the surgeon must place them in a way that facilitates their imaging. One of Dr. Haas’ radiation therapists, Lauren Boone, devised a method to place the markers during computed tomography (CT) simulation in a 10-minute outpatient procedure with no anesthesia. The procedure has worked remarkably well at NYU Winthrop, says Dr. Haas, who has taught it to other physicians.

Also promising is real-time imaging with magnetic resonance (MR)-guided radiation therapy systems, notes Dr. Feigenberg. “It’s not just doing volumetric imaging with cone-beam CT, which was a big improvement for visualizing the tumor before and after treatment, but having 3D image guidance during treatment,” he says. “It’s a very interesting development, especially to see exactly what dose is delivered.”

Studies in the Works

Although Dr. Haas has not yet conducted a clinical trial that escalates the dose—“It’s hard to argue with a 98% success rate,” he says—his department will participate in a study with UT Southwestern Medical Center and Asal Rahimi, MD, MS, director of clinical research, to examine single-fraction SBRT treatment intraoperatively. After lumpectomy, eligible patients will be enrolled to evaluate a single 20 to 30 Gy dose delivered to the surgical cavity. While Dr. Haas is admittedly not a fan of delivering treatment without knowing the final pathology, “the data supports it as effective, and we know it can be done safely in intraoperative therapy.” He adds that continued clinical studies of SBRT will likely examine further acceleration of the treatment regimen. In fact, Dr. Rahimi and colleagues recently published results of a phase 1 dose escalation trial for early stage breast cancer using 40 Gy in 5 fractions. The results demonstrated minimal toxicity and invasiveness, and excellent local control rates and cosmesis.

At UMSOM, Dr. Nichols participated in a clinical study for preoperative partial breast radiation that used standard APBI dose fractionation. Results demonstrated a 15% pathologic complete response—meaning there was no viable cancer left behind or no cancer at all. Other research in Europe found a similar 15% to 20% pathologic
complete response using nonablative doses of radiation.\(^5\)

“Between those two studies, we think something is there that requires further investigation,” Dr. Nichols says. “We can’t make the direct jump from SBRT to no surgery, so one of our clinical trials is to deliver ablative doses of radiation followed by surgery with the hope that we can see similar results.” The next step would be a trial examining SBRT without surgery.

Dr. Feigenberg is equally excited about the potential to successfully treat breast cancer with SBRT and avoid surgery. He notes that nearly all data comparing whole-breast with partial-breast radiation show no difference in local control except for trials that tested intraoperative radiation therapy. Specifically, two randomized trials had higher local failure rates of recurrence in the same breast—a major limitation was the lack of image guidance, resulting in the inability to document dose to the lumpectomy cavity and adjacent structures.\(^6,7\)

The Technology Behind Breast SBRT

Several radiation therapy systems are available for breast SBRT. With the CyberKnife, the beam can be delivered from many different angles (non-coplanar treatment), minimizing dose to other parts of the body. “It is robotic and intelligent, with two imagers that track the movement of four fiducial markers placed around the cavity,” says Dr. Haas. It also has a respiratory tracking system using leads placed on the chest and stomach, enabling accuracy of < 1 mm in tracking movement.

“CyberKnife remains the only robotic delivery system that detects submillimetric changes in the patient and target position, and automatically adjusts the aim of the linac to account for them throughout the treatment session,” says Fabienne Hirigoyenberry-Lanson, PhD, vice president of Accuray’s Global Medical and Scientific Affairs. “Coupled with by-design noncoplanar delivery of linac beams, the CyberKnife can deliver highly conformal beams with incredible accuracy.” The result of this accuracy has reduced margins and dose to surrounding normal tissue.

Dr. Hirigoyenberry-Lanson adds that there are increased concerns regarding treating very low risk, small and localized lesions, and whether such lesions should even be treated. “This situation puts a premium on treatments that are noninvasive and have the last chance of altering a patient’s quality of life. The CyberKnife system can, in most cases, deliver such a treatment.”

The Versa HD system (Elekta, Stockholm, Sweden) (Figure 2) delivers highly conformal doses in hypofractionated settings in standard treatment slots and, according to John Christodoulou, MD, vice president of Elekta’s Medical Affairs and Clinical Research, offers advantages in mitigating motion-related inaccuracies and increasing patient comfort by lessening on-table time.

“The large imaging and treatment field of view of Versa HD enables accurate and efficient treatment of more advanced indications where the lymphatic system needs to also be treated in addition to the primary target,” says Dr. Christodoulou. Versa HD is also integrated with the company’s Active Breathing Coordinator (ABC), which provides automated gating. This helps patients pause breathing at a specific tidal volume to maximize distance between the tumor and adjacent critical structures.

Addressing the growing awareness for integrating MRI into radiation therapy, Elekta’s MR-linac, which is pending FDA approval, has the potential to address the movement of breast tissue as the patient breathes during the treatment cycle. Dr. Christodoulou explains that it integrates precision radiation dosing via a state-of-the-art linear accelerator with

---

**FIGURE 2. The Elekta Versa HD system**

---
imaging from a high-field, 1.5T MRI without compromising either system.


Fresh off its clearance by the Food and Drug Administration (FDA) in December 2017, GammaPod (Xcision Medical Systems, Columbia, Maryland) (Figure 3) is designed specifically for SBRT treatments of the breast. Both Drs. Nichols and Feigenberg were involved in the clinical trial used in the FDA submission, as well as in evaluating dosimetric improvements of the device comparing APBI delivered by brachytherapy or intensity-modulated radiation therapy (IMRT). With GammaPod, they demonstrated a substantial decrease in dose to the skin, and less heterogeneity of dose compared to brachytherapy, theoretically increasing patient eligibility for noninvasive treatment with a better side effect profile.

GammaPod delivers more conformal doses of radiation in less time, says Steve Rubenstein, vice president of marketing for Xcision. “GammaPod provides the first stereotactic radiotherapy system that has been optimized to noninvasively deliver a dose distribution to a target within the breast,” he says. “We are unaware of other technologies that can noninvasively deliver conformal dose distributions with sharp falloff using a stereotactic localization and immobilization system for the breast. With highly conformal dose distributions, GammaPod treatments can lower dose to the heart, lungs and surrounding healthy breast tissue.”

Unique to GammaPod is its noninvasive breast cup system that provides a secure immobilization to minimize motion during treatment and is imbedded with a fiducial wire for stereotactic target localization. Additionally, it delivers highly conformal dose distribution using dynamic dose painting.

“During treatment, the radiation sources and collimators rotate to deliver radiation from thousands of beam angles,” Rubenstein explains. “An intense focal dose is created at the point where the beams converge. By moving the patient table during treatment along a dynamically traveling path, the target volume passes in and out of the focal spot so the dose is painted to the target.”

Patients are imaged and treated with identical 3D setup geometry, adds Rubenstein, and all treatments are performed in the prone position, which has been shown to limit dose to the heart and lungs.

**A look ahead**

Xcision has established a consortium of academic institutions to lead the evidence development process, Rubenstein says. The group consists of the University of Maryland School of Medicine in Baltimore; UT Southwestern Medical Center in Dallas; Allegheny General Hospital in Pittsburgh; and The Ottawa Hospital in Ontario, Canada.

Dr. Christodouleas says that while hybrid CT-MR planning is more rapidly being used for precision breast treatments, “without having the same imaging horsepower available to assess anatomy at the time of treatment, it becomes more difficult to develop more aggressive treatments.”

Elekta’s MR-linac consortium of 12 centers features a research infrastructure in which physicians can develop a new breast SBRT paradigm that “adapts its target and total dose based on biologic responses assessed on quantitative MR imaging.”

**FIGURE 3. The GammaPod by Xcision Medical Systems**


sequences, such as diffusion-weighted imaging (DWI),” he adds.

Birgit Fleurent, chief marketing officer at Accuray, points out that ASTRO, through its Choosing Wisely initiative, has recognized that, “equivalent tumor control and cosmetic outcome in specific patient populations can be achieved with shorter courses of therapy (approximately 4 weeks) vs ‘conventionally fractionated’ schedules delivered over 5 to 6 weeks, often followed by 1 to 2 weeks of boost therapy. Investigators at leading academic hospitals researching CyberKnife SBRT, following lumpectomy, are also seeing similar tumor control and cosmetic outcomes vs conventional therapy, but for the course of only 1 to 2 weeks.”

With advanced technology such as Versa HD, CyberKnife, GammaPod and the potential for real-time MR-guided treatments, along with numerous clinical studies delivering data to guide treatment decisions, SBRT is emerging as a promising option for breast cancer treatment.

**REFERENCES**